Drug safety in thyroid eye disease - a systematic review

Expert Opin Drug Saf. 2022 Jul;21(7):881-912. doi: 10.1080/14740338.2022.2069239. Epub 2022 Aug 15.

Abstract

Introduction: The autoimmune-induced thyroid eye disease (TED) is a frequent extrathyroidal manifestation of Graves' disease and less frequently of Hashimoto's thyroiditis. Pathognomonic clinical signs, i.e. exophthalmos, double vision, and inflammation of the orbital tissue cause physical, ophthalmic, and socio-psychological limitations.

Areas covered: PubMed and MeSH database were searched for specific guidelines, randomized controlled trials, prospective clinical studies, systematic reviews, and meta-analyses pertaining to the safety profile of currently administered immunosuppressive agents for the treatment of TED. Occurred adverse events (AE), severe AE (SAE), side effects (SE), and severe SE (SSE) were classified according to the standardized medical dictionary for regulatory activities (MedDRA).

Expert opinion: This novel systematic analysis offers an overview of potential AE, SAE, and SE for currently recommended immunosuppressive drugs for the treatment of TED. Nonspecific, anti-inflammatory drugs and more specific, targeted biologicals are treatment options for active and severe TED. Critical evaluation of the pertinent literature confirms an evidence-based, beneficial efficacy/risk ratio of the current first-line and second-line treatment recommendations endorsed by the European Society of Endocrinology. However, further large, well-conceived trials are mandatory to enhance our knowledge and experience with novel specific small molecules and/or monoclonal antibodies targeting the key autoantigens in TED.

Keywords: Drug safety; adverse event; side effect; thyroid eye disease; thyroid-associated orbitopathy.

Publication types

  • Systematic Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Graves Disease* / drug therapy
  • Graves Ophthalmopathy* / diagnosis
  • Graves Ophthalmopathy* / drug therapy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Prospective Studies

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents